All news

CenterBook trims Regeneron stake by 17.1%

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

CenterBook Partners LP cut its Regeneron Pharmaceuticals (NASDAQ:REGN) position by 17.1% in the third quarter, selling 2,649 shares. The biopharmaceutical company still posted quarterly earnings of $20.07 per share, beating analyst estimates, while revenue climbed 36.3% year over year. Analysts rate the stock a Moderate Buy with an average price target of $898.97, suggesting limited upside from current levels.

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.